Ignite Creation Date:
2025-12-18 @ 8:20 AM
Ignite Modification Date:
2025-12-23 @ 10:50 PM
Study NCT ID:
NCT01755923
Status:
None
Last Update Posted:
2012-12-24 00:00:00
First Post:
2012-12-17 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Sponsor:
Organization:
Raw JSON
{}